International registry for men with advanced prostate cancer: IRONMAN Study
The IRONMAN registry will prospectively recruit minimum of 5000 patients with advanced prostate cancer. Patients are recruited during an initial study period of three years and followed up for a minimum of five years. Info on all patients is collected at study enrolment (demographic, medical hx, etc). Physician questionnaires are collected. Baseline bloods will be taken.
Study objectives: To describe practice patterns of therapeutic agents for treatment of advanced prostate cancer internationally. Assess whether specific treatment patterns are associated with clinically significant adverse events, and evaluate potential interactions with concomitant medications or demographic factors. Identify associations between different treatment sequences or combinations and overall survival. Define the patient experience of men with advanced prostate cancer and identify unmet needs in their treatment. Identify clinical and molecular disease sub-types that predict response to individual treatments, combinations or sequences.
Status: Recruitment open.
TREAT ctDNA
The TREAT ctDNA trial is led and funded by the European Organisation for Research and Treatment of Cancer (EORTC) and is Sponsored in Ireland by Cancer Trials Ireland (CTI). This international, multicentre, randomized, phase III clinical trial is screening patients with ER+/HER2- breast cancer at different timepoints by testing for the presence of circulating tumor DNA (ctDNA) in their blood, which if positive can indicate relapse. Patients found to be ctDNA positive, with no evidence of metastasis or recurrence on imaging, will progress to the randomised phase of the trial during which they will be randomized 1:1 to be treated with an oral drug called elascestrant or physician’s choice of standard endocrine treatment to determine if elascetrant can delay the development of distant metastases.
This trial is supported by Menarini Stemline and Natera Oncology.
Status: Open to Recruitment
WAYFIND-R
WAYFIND-R is a global registry sponsored by Roche that will collect data from patients who have been diagnosed with a solid tumour and whose tumour has been profiled with a next-generation sequencing (NGS) test.
Status: Open to Recruitment
T
